A Phase lb Trial of the Combination of Bryostatin-1 and Low Dose Interleukin-2: Evaluation of the Functional and Molecular Status of Human Monocytes as Antigen Presenting Cells
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bryostatin-1; Interleukin-2
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 29 Apr 2015 Biomarkers information updated
- 02 Aug 2008 Status changed from suspended to completed based on information from ClinicalTrials.gov.
- 01 Jun 2008 Status change from recruiting to suspended, according to clinicaltrials.gov.